Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 8/20 | 0.64 |
| ▸ | FYN | P06241 | 1/20 | 0.62 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.59 |
| ▸ | IKBKB | O14920 | 11/20 | 0.55 |
| ▸ | CHUK | O15111 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2947988 | 0.82 | PIM1 (0.75) | PIM1FYNPIM2IKBKBCHUK | |
| SCHEMBL2949833 | 0.82 | PIM1 (0.71) | PIM1FYNPIM2IKBKB | |
| SCHEMBL103273 | 0.81 | PIM1 (0.73) | PIM1FYNPIM2IKBKBCHUK | |
| SCHEMBL2941582 | 0.81 | FYN (0.77) | PIM1FYNPIM2IKBKB | |
| SCHEMBL2943516 | 0.80 | FYN (0.67) | PIM1FYNPIM2IKBKBCHUK | |
| SCHEMBL2947187 | 0.80 | PIM1 (0.72) | PIM1FYNPIM2IKBKBCHUK | |
| SCHEMBL2944042 | 0.79 | FYN (0.68) | PIM1FYNPIM2IKBKB | |
| SCHEMBL19467158 | 0.79 | PIM1 (0.71) | PIM1FYNPIM2IKBKBCHUK | |
| SCHEMBL15254391 | 0.79 | FYN (0.59) | PIM1FYN | |
| SCHEMBL2949044 | 0.79 | FYN (0.68) | PIM1FYNPIM2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | PIM1 365/4885FYN 421/4885PIM2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.